Journal of Neurology

, Volume 240, Issue 5, pp 305–308 | Cite as

Decreased vitamin B12 and folate levels in cerebrospinal fluid and serum of multiple sclerosis patients after high-dose intravenous methylprednisolone

  • Stephan T. F. M. Frequin
  • Ron A. Wevers
  • Majorie Braam
  • Frederik Barkhof
  • Otto R. Hommes
Original Communications


Twenty-one patients (15 women, 6 men) with definite multiple sclerosis (MS) were treated with 1000 mg intravenous methylprednisolone-succinate (MP) daily for 10 days. Before MP treatment there was a negative correlation (r = 0.59,P = 0.0084) between serum vitamin B12 and progression rate, defined as the ratio of the score on Kurtzke's Expanded Disability Status Scale and disease duration. A significant decrease was demonstrated in the cerebrospinal fluid (CSF) and serum levels of folate and in the CSF level of Viamin B12 after MP treatment. The decrease in serum B12 was not statistically significant. After MP treatment all median levels of vitamin B12 and folate were below the reference medians. We hypothesize that low or reduced vitamin B12/folate levels found in MS patients may be related to previous corticosteroid treatments. Otherwise a more causal relationship between low Viamin B12/folate and MS cannot be excluded. Further studies may be required to clarify the vitamin B12 and folate metabolism in patients with MS.

Key words

Vitamin B12 Folate Multiple sclerosis Methylprednisolone 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Barkhof F, Hommes OR, Scheltens P, Valk J (1991) Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology 41:1219–1222PubMedGoogle Scholar
  2. 2.
    Burnham JA, Wright RR, Dreisbach J, Murray RS (1991) The effect of high-dose steroids on MRI gadolinium enhancement in acute demyelinating lesions. Neurology 41:1349–1354PubMedGoogle Scholar
  3. 3.
    Chanarin I (1979) The megaloblastic anemias, 2nd edn, Blackwell, Oxford, pp 324–327Google Scholar
  4. 4.
    Crellin RF, Bottiglieri T, Reynolds EH (1990) Multiple sclerosis and macrocytosis.Acta Neurol Scand 81:388–391PubMedGoogle Scholar
  5. 5.
    Durelli L, Cocito D, Riccio A, Barile C, Bergamasco B, Baggio GF, Perla F, Delsedime M, Gusmaroli G, Bergamini L (1986) High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunological correlations. Neurology 36:238–243PubMedGoogle Scholar
  6. 6.
    Frequin STFM, Hommes OR, Lamers KJB, Doesburg W (1991) High-dose intravenous methylprednisolone treatment in multiple sclerosis. In: Wiethölter H, Dichgans J, Mertin J (eds) Current concepts in multiple sclerosis. Elsevier, Amsterdam, pp 253–255Google Scholar
  7. 7.
    Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452PubMedGoogle Scholar
  8. 8.
    Lazar GS, Carmel R (1981) Cobalamin binding and uptake in vitro in the human central nervous system. J Lab Clin Med 97:123–133PubMedGoogle Scholar
  9. 9.
    Nijsr TQ, Wevers RA, Schoonderwaldt HC, Hommes OR, Haan AU de (1990) Vitamin B12 and folate concentrations in serum and cerebrospinal fluid of neurological patients with special reference to multiple sclerosis and dementia. J Neurol Neurosurg Psychiatry 53:951–954PubMedGoogle Scholar
  10. 10.
    Poser CM, Paty DW, Scheinberg L, et al (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231PubMedGoogle Scholar
  11. 11.
    Reynolds EH, Linnell JC, Faludy JE (1991) Multiple sclerosis associated with vitamin B12 deficiency. Arch Neurol 48:808–811PubMedGoogle Scholar
  12. 12.
    Scott JM, Dinn JJ, Wilson P, Weir DG (1981) Pathogenesis of subacute combined degeneration: a result of methyl group deficiency. Lancer II:334–337Google Scholar
  13. 13.
    Smith I, Howell DW, Kendall B, Levinsky R, Hyland K (1987) Folate deficiency and demyelination in AIDS. Lancer II:215Google Scholar
  14. 14.
    Surtees R, Hyland K, Smith I (1990) Central-nervous-system methyl-group metabolism in children with neurological complications of HIV infection. Lancet 335:619–621PubMedGoogle Scholar
  15. 15.
    Surrees R, Leonard J, Austin S (1991) Association of demyelination with deficiency of cerebrospinal-fluid S-adenosylmethionine in inborn errors of methyl-transfer pathway. Lancet 338:1550–1554PubMedGoogle Scholar
  16. 16.
    Warren KG, Catz I, Carroll DJ (1987) Effects of high-tomega-dose synthetic corticosteroids on multiple sclerosis patients with special reference to cerebrospinal fluid antibodies to myelin basic protein. Clin Neuropharmacol 10:397–411PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Stephan T. F. M. Frequin
    • 1
  • Ron A. Wevers
    • 1
  • Majorie Braam
    • 1
  • Frederik Barkhof
    • 2
  • Otto R. Hommes
    • 1
  1. 1.Department of NeurologyUniversity Hospital NijmegenHB NijmegenThe Netherlands
  2. 2.Department of Diagnostic RadiologyFree University HospitalAmsterdamThe Netherlands

Personalised recommendations